The prognosis of metastatic melanoma patients treated with immunotherapy has improved considerably. Based on the 6.5-yr update to the CHECKMATE-067 study (presented at ASCO 2021 meeting), the OS for patients treated with ipi/nivo is 49%, 42% for nivo alone, and 23% for ipi alone. If the patient has ...